- Dietmar Hopp investierte erstmals 2005 in CureVac und ist nach wie vor ein starker Befürworter des Unternehmens und der Zukunft seiner mRNA-Technologie.
- ^ "CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide". CureVac (Press release).
- time, Tesla and CureVac filed a joint patent on the technology.[25] In August, Musk reviewed the project with Curevac while in Germany.[25].
- CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise...
- Prophylactic vaccines, cancer therapies & molecular therapies: CureVac is a leader & pioneer in developing medicines based on mRNA. https://t.co/8NlCE03ZY6.
- CureVac N.V., a clinical-stage biopharmaceutical firm, is focused on the development of a diverse range of revolutionary therapies based on messenger ribonucleic...
- CureVac ist ein führendes biopharmazeutisches Unternehmen auf dem Gebiet der mRNA-Technologie (Boten-RNA, von engl. messenger RNA).
- CureVac NV hisse senedi fiyatı, bu sayfada NASDAQ CVAC borsa verileri gösteriliyor. ... CureVac NV içindeki en son hareketleri izleyin.
- haziran 2021 gibi çıkması planan aşıdır. curevac çıktığı zaman coronavirüse karşı dünyadaki en başarılı aşı olacağına inancım çok yüksek.
- CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).